Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Overactive Bladder Market New Entrants Are Targeting Specialty Physicians

Executive Summary

Recent entrants to the overactive bladder category are focusing on capturing market share through specialty physicians, Indevus Exec VP and Chief Sales & Marketing Officer John Tucker said

You may also be interested in...



FDA tells Pfizer to hold it

Pfizer receives an "approvable" letter from FDA for the overactive bladder treatment fesoterodine, which it acquired from Schwarz in April. Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012 (1"The Pink Sheet" Aug. 15, 2005, p. 5)...

FDA tells Pfizer to hold it

Pfizer receives an "approvable" letter from FDA for the overactive bladder treatment fesoterodine, which it acquired from Schwarz in April. Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012 (1"The Pink Sheet" Aug. 15, 2005, p. 5)...

Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports

Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel